重症哮喘应用贝那利珠单抗治疗二例

doi:10.19983/j.issn.2096-8493.20210074

结核与肺部疾病杂志 ›› 2022, Vol. 3 ›› Issue (1): 80-84.doi: 10.19983/j.issn.2096-8493.20210074

重症哮喘应用贝那利珠单抗治疗二例

林慧敏¹, 谢佳星¹^,²^,³()

¹国家呼吸系统疾病临床医学研究中心/呼吸疾病国家重点实验室/广州医科大学附属第一医院呼吸与危重症医学科/广州呼吸健康研究院,广州 510120
²国家呼吸系统疾病临床医学研究中心/呼吸疾病国家重点实验室/广州医科大学附属第一医院变态反应科/广州呼吸健康研究院,广州 510120
³广东医科大学附属阳江医院/阳江市人民医院呼吸与危重症医学科,阳江 529500

收稿日期:2021-07-25 出版日期:2022-02-20 发布日期:2022-02-24
通信作者: 谢佳星 E-mail:jiaxingxie@126.com

Received:2021-07-25 Online:2022-02-20 Published:2022-02-24

摘要/Abstract

关键词: 哮喘, 抗体,单克隆, 治疗应用, 病例报告

中图分类号:

R256.12

林慧敏, 谢佳星. 重症哮喘应用贝那利珠单抗治疗二例[J]. 结核与肺部疾病杂志, 2022, 3(1): 80-84. doi: 10.19983/j.issn.2096-8493.20210074

图/表 2

参考文献 15

[1]	Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humani-zed anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol, 2010, 125(6):1344-1353. doi: 10.1016/j.jaci.2010.04.004. doi: 10.1016/j.jaci.2010.04.004 pmid: 20513525
[2]	Martínez-Rivera C, Garcia-Olivé I, Urrutia-Royo B, et al. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis. BMC Pulm Med, 2021, 21(1):35. doi: 10.1186/s12890-021-01397-7. doi: 10.1186/s12890-021-01397-7 pmid: 33478439
[3]	Lombardo N, Pelaia C, Ciriolo M, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol, 2020, 34:1682188099. doi: 10.1177/2058738420950851. doi: 10.1177/2058738420950851
[4]	Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med, 2017, 376(25):2448-2458. doi: 10.1056/NEJMoa1703501. doi: 10.1056/NEJMoa1703501 URL
[5]	FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2016, 388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. doi: S0140-6736(16)31322-8 pmid: 27609406
[6]	Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β₂-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet, 2016, 388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. doi: S0140-6736(16)31324-1 pmid: 27609408
[7]	Pelaia C, Busceti MT, Vatrella A, et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm Pharmacol Ther, 2019, 58:101830. doi: 10.1016/j.pupt.2019.101830. doi: 10.1016/j.pupt.2019.101830 URL
[8]	Menzies-Gow A, Corren J, Bel EH, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res, 2019, 5(3):00009-2019. doi: 10.1183/23120541.00009-2019. doi: 10.1183/23120541.00009-2019
[9]	Matsuno O, Minamoto S. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps. Pulm Pharmacol Ther, 2020, 64:101965. doi: 10.1016/j.pupt.2020.101965. doi: 10.1016/j.pupt.2020.101965 pmid: 33039667
[10]	Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med, 2021, 9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. doi: 10.1016/S2213-2600(20)30414-8 pmid: 33357499
[11]	Eger K, Pet L, Weersink E, et al. Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract, 2021, 9(7):2913-2915. doi: 10.1016/j.jaip.2021.02.042. doi: 10.1016/j.jaip.2021.02.042 URL
[12]	Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43(2):343-373. doi: 10.1183/09031936.00202013. doi: 10.1183/09031936.00202013 pmid: 24337046
[13]	Bilocca D, Hargadon B, Pavord ID, et al. The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma. Chron Respir Dis, 2018, 15(1):85-87. doi: 10.1177/1479972317709650. doi: 10.1177/1479972317709650 URL
[14]	嗜酸性肉芽肿性多血管炎诊治规范多学科专家共识编写组. 嗜酸性肉芽肿性多血管炎诊治规范多学科专家共识. 中华结核和呼吸杂志, 2018, 41(7):514-521. doi: 10.3760/cma.j.issn.1001-0939.2018.07.002. doi: 10.3760/cma.j.issn.1001-0939.2018.07.002
[15]	Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med, 2019, 7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. doi: 10.1016/S2213-2600(18)30406-5 URL

重症哮喘应用贝那利珠单抗治疗二例

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 15

相关文章 10

编辑推荐

Metrics

本文评价

友情链接

[1]	陈壮濠, 林健雄, 曾丽翔. 含左氧氟沙星短程方案治疗初治菌阳肺结核的临床效果[J]. 结核与肺部疾病杂志, 2022, 3(1): 19-21.
[2]	黄林欢, 周厚仕, 林琬, 林麒. 非结核分枝杆菌病17例临床分析[J]. 结核与肺部疾病杂志, 2021, 2(4): 352-354.
[3]	周洁, 祁勍, 陈龙, 武蕊, 史光烁, 杜鹤, 刘亚欣, 熊雷, 吴志乐, 吴国霞. 内科医师对全球哮喘防治倡议知晓情况调查[J]. 结核与肺部疾病杂志, 2021, 2(2): 189-192.
[4]	热娜·阿卜来提, 克丽别娜·吐尔逊, 迪丽努尔·乌甫尔. 支气管哮喘与心理障碍相关性的研究进展[J]. 结核与肺部疾病杂志, 2020, 1(3): 285-288.
[5]	仲崇霞, 王华山. 2018—2019年江苏省沭阳县二级以上综合医院肺结核报告及转诊质量分析[J]. 结核与肺部疾病杂志, 2020, 1(2): 179-182.
[6]	张红辉,黄威. 吸入用布地奈德混悬液治疗儿童哮喘的临床效果分析[J]. 结核病与肺部健康杂志, 2019, 8(3): 188-191.
[7]	陈宇,樊丽超,陈禹,朱雅娟. 持续腰大池引流术在结核性脑膜炎治疗中的应用[J]. 结核病与肺部健康杂志, 2018, 7(3): 221-224.
[8]	张桐. 18例重症支气管哮喘患者的临床疗效分析[J]. 结核病与肺部健康杂志, 2018, 7(1): 77-78.
[9]	陈育智. 儿童哮喘诊断治疗和教育[J]. 结核病与肺部健康杂志, 2012, 1(1): 32-35.
[10]	时国朝,王林林. 支气管哮喘诊断和治疗新进展[J]. 结核病与肺部健康杂志, 2012, 1(1): 27-31.